It indicates patients cannot easily come off these therapies without rebound side effects
Glucagon-Like Peptide-1 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with Meta-Analysis
14, 2025, San Diego), Novo Nordisk presented full Phase 3 results from EVOKE and EVOKE+, enrolling 3,808 participants with early Alzheimers (MCI or mild dementia) and confirmed amyloid pathology
19 studies found reductions in hyperphosphorylated tau, the form of tau protein that creates harmful tangles within neurons
Studies demonstrate 10-15% body weight reductions, positioning it as a powerful tool for obesity mechanism investigations
To limit computational costs, only cells profiled with the Smart-seq platform (73,000 cells) were used